Second Line and Beyond / Multiple Myeloma 06/26/2026

Evolving Treatment Landscape in Second-Line and Beyond Multiple Myeloma

Key Points

  • Bispecific antibody and chimeric antigen receptor (CAR) T-cell therapies have emerged as preferred treatment options for multiple myeloma after first relapse.
  • Talquetamab, a novel GPRC5D–directed bispecific antibody, is an alternative to B-cell maturation antigen (BCMA)–directed agents, but involves distinct oral, skin, and nail toxicities.
  • Management of infection and fever risk is critical to successful use of bispecific antibodies in relapsed or refractory multiple myeloma.
  • Cereblon E3 ligase modulators (CELMoDs) are emerging as more potent versions of existing immunomodulatory drugs, which may improve the value of triplet therapy in refractory patients.

Unpacking Bispecific Antibodies and Other Advancements in Multiple Myeloma

Cohosts of the Oncology Brothers podcast, Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, hosted a roundtable discussion focused on the evolving treatment of multiple myeloma in the second-line and beyond. The roundtable included myeloma experts Beth Faiman, CNP, PhD, of Cleveland Clinic; Rafael Fonseca, MD, of Mayo Clinic Arizona; and S. Vincent Rajkumar, MD, of Mayo Clinic Rochester. 

Before unpacking the relapsed or refractory multiple myeloma treatment paradigm, Dr. Rahul Gosain noted that the standard upfront therapy is quadruplet regimens that combine an anti-CD38 monoclonal antibody like daratumumab with bortezomib, lenalidomide, and dexamethasone. This is often followed by maintenance therapy with lenalidomide with or without daratumumab. The treatments that patients receive in frontline therapy can affect later-line options, particularly as daratumumab use continues to grow. 

The Second-Line Treatment Paradigm for Multiple Myeloma

At first relapse, the historical approach was to use a triplet regimen containing agents the patient did not receive in first-line therapy, such as daratumumab, lenalidomide, and dexamethasone or daratumumab, pomalidomide, and dexamethasone (DPd). However, in recent years, studies have established the value of CAR T-cell and bispecific antibody therapies. Both of these novel agents showed superiority versus triplet regimens for patients with relapsed or refractory multiple myeloma in randomized controlled trials. Based on these data, either CAR T-cell or bispecific therapy are now preferred options for relapsed or refractory patients.

Growing Data for Teclistamab in Early-Relapse Multiple Myeloma

Teclistamab, a BCMA and CD3–directed bispecific antibody, was initially approved in 2022 for patients with relapsed or refractory multiple myeloma after at least 3 prior lines of therapy based on the MajesTEC-1 trial. On March 5, 2026, the combination of teclistamab and daratumumab was approved for patients after 1 prior line of therapy based on groundbreaking data from the MajesTEC-3 trial, bringing bispecifics into the second-line setting. 

Most recently, data from the MajesTEC-9 study showed that teclistamab monotherapy improved survival compared with pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (Kd) for patients with 1 to 3 prior lines of therapy. These data support teclistamab as a second-line option for daratumumab–refractory patients. 

Talquetamab: A Novel Bispecific With Distinct Targeting

The current advancements with bispecifics and CAR T-cell therapies have all been based on BCMA–directed agents. Talquetamab is a novel bispecific antibody that instead targets GPRC5D and CD3. Talquetamab plus daratumumab with or without pomalidomide significantly improved progression-free survival (PFS) compared with DPd in the interim analysis of the MonumenTAL-3 trial, presented at the 2026 European Hematology Association Congress. 

Talquetamab is associated with cytokine release syndrome (CRS), neurotoxicity, and infections, although at a slightly lower rate than BCMA–directed bispecifics. However, because of its GPRC5D targeting, talquetamab is also associated with challenging oral, skin, and nail side effects that require new management strategies. Given the more profound impact these side effects can have on a patient’s quality of life, the panelists preferred to start with BCMA–directed agents and reserve talquetamab for later lines of therapy. 

Prophylactic Strategies to Manage Side Effects of Bispecifics

When using either BCMA–directed bispecific antibodies or talquetamab for relapsed or refractory multiple myeloma, proactive prophylaxis strategies are crucial. For CRS, data continue to emerge supporting the use of prophylactic tocilizumab to reduce risk, such as the OPTec/OPTal trial. Managing infection risk is even more critical, especially with BCMA–directed bispecifics. The doctors agreed that intravenous immunoglobulin G replacement therapy is a necessary partner to bispecific therapy, and should be continued as long as patients are on treatment. Outside of CRS and infections, antifungal and antiviral prophylaxis, along with updated vaccinations are also recommended.

CELMoDs Emerge as Promising Agents for Refractory Patients

The growth of quad-class regimens in the frontline treatment of multiple myeloma may limit the efficacy of traditional triplet regimens in the relapsed or refractory setting, leaving an unmet need for patients that can’t receive CAR T cells or bispecific antibodies. CELMoDs are emerging as a potential answer to this gap. CELMoDs follow the same pathway as existing immunomodulatory drugs like lenalidomide and pomalidomide, but have a more potent mechanism that may overcome treatment resistance. 

In the phase 3 SUCCESSOR-2 trial, the addition of mezigdomide to Kd showed a meaningful PFS benefit, including in second-line therapy, according to data presented at the 2026 American Society of Clinical Oncology. While data for the CELMoD class as a whole are still sparse, Dr. Fonseca suggested CELMoDs are likely to evolve the paradigm for a variety of multiple myeloma treatment settings, and may improve the success of bridging strategies prior to CAR T-cell therapies.